INDV Q4 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$358M+19.7% YoY

Gross Profit

$294M82.1% margin

Operating Income

$122M34.1% margin

Net Income

$103M28.8% margin

EPS (Diluted)

$0.79

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

-$221M

Free Cash Flow

-$245M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.3B

Stockholders' Equity

-$98M

Cash & Equivalents

$195M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$358M	$299M	+19.7%
Gross Profit	$294M	$276M	+6.5%
Operating Income	$122M	$96M	+27.1%
Net Income	$103M	$59M	+74.6%

Revenue Segments

Reportable Segment

$357M100%